TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer TuHURA Biosciences...
PR Newswire·1y ago
More News
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor TuHURA Biosciences Enters into Exclusivity and Right of...
PR Newswire·1y ago
12 titres de soins de sant en mouvement lors de la session apr s-cl ture le 08/04/2024
Gagnants
L'action Kineta (NASDAQ:KA) a mont lundi de 16,77% 0,63 dollars lors de la session after-market.
Le titre Windtree Therapeutics (NASDAQ:WINT) a mont de 14,63% 0,47 dollars.
Le titre...
Benzinga·1y ago
12 titoli sanitari in movimento, after-market del 08/04/2024
Titoli in rialzo
Le azioni di Kineta (NASDAQ:KA) hanno guadagnato l'11,21% a 0,60 dollari durante la sessione after-market di luned .
Le azioni di Finch Therapeutics Gr (NASDAQ:FNCH) sono salite...
Benzinga·1y ago
12 titres de soins de sant en mouvement lors de la session apr s-cl ture le 03/04/2024
Gagnants
L'action Kineta (NASDAQ:KA) a grimp mercredi de 8,46% 0,58 dollars lors de la session after-market.
Le titre Simulations Plus (NASDAQ:SLP) a mont de 8,07% 41,50 dollars. La soci t a...
Benzinga·1y ago
Kineta, Inc. (NASDAQ:KA) Short Interest Update
Kineta, Inc. (NASDAQ:KA Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 75,300 shares, a...
Ticker Report·1y ago
KA Stock Earnings: Kineta Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
KA stock results show that Kineta beat analyst estimates for earnings per share the fourth quarter of 2023.
The post KA Stock Earnings...
InvestorPlace·1y ago
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No dose limiting toxicities observed at any dose...
Globe Newswire·1y ago
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohortsNo dose limiting toxicities observed at any dose levelCleared fifth of...
Globe Newswire·1y ago
Week in Review: Most popular stories on GeekWire for the week of Feb. 25, 2024
Get caught up on the latest technology and startup news from the past week. Here are the most popular stories on GeekWire for the week of Feb. 25, 2024.
Sign up to receive these updates every Sunday...